Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
Abstract
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by ∼0.8–1.6%), body weight (by ∼1–3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GI AE profile of semaglutide 2.4 mg in the STEP trials is consistent with previous observations with lower semaglutide doses and the established AE profile of GLP‐1RAs. 14 , 28 , 29”
From Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As higher incidences of GI AEs tend to be experienced with higher doses of GLP‐1RAs, gradual dose escalation and dose adjustment may help mitigate the impact of GI AEs in clinical practice. 29 , 30”
In the citing paper
“GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements to β-cell function and peripheral insulin sensitivity ( Zander et al., 2002 ; Hinnen, 2017 ).”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Hinnen, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similar positive cardiovascular results were reported recently for semaglutide, an investigational GLP-1 receptor agonist administered QW (33).”
ResultMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Two incretin hormones have been identified: glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) (4).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“O R G The incretin system has become an important target in the treatment of type 2 diabetes in recent years (1).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is reduced in people with type 2 diabetes (6).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Research works printed but not linked: 2
- Johnson, 2014, Integrated phase 3 immunogenicity results for albiglutide, Diabetes, 63, A427
- Milicevic, 2015, Low incidence of anti-drug antibody in type 2 diabetes patients treated with once-weekly dulaglutide, Diabetes, 64, A292
Cited by
Items 101–200 of 410
Karimi, M. A., Chahkand, M. S. G., Dadkhah, P. A., Sheikhzadeh, F., Yaghoubi, S., Moallem, F. E., Deyhimi, M. S., Bafrani, M. A., Shahrokhi, M., & Nasrollahizadeh, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1438318 · Cited by 27
“However, notable challenges are associated with prescribing these medications, including their higher costs and potential tolerability issues (Care, 2019; Janzen et al., 2016; Hinnen, 2017).”
Nowak, M., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0014 · Cited by 30
Management of Diabetes in Patients Undergoing Bariatric Surgery
Mulla, C. M., Baloch, H. M., & Hafida, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1242-2 · Cited by 27
Tryptophan Indole Derivatives: Key Players in Type 2 Diabetes Mellitus
Wu, Y., Li, T., Chen, B., Sun, Y., Song, L., Wang, Y., Bian, Y., Qiu, Y., & Yang, Z. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s511068 · Cited by 27
“44,65,66 Diabetic patients often exhibit a significant loss of GLP-1 functionality, which is crucial for enhancing glucose metabolism and overall metabolic health through the protection of β cells, reduction of apoptosis, and promotion of β cell proliferation and regeneration.”
Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes
Kamruzzaman, M., Horowitz, M., Jones, K. L., & Marathe, C. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.661877 · Cited by 24
“exenatide QW, dulaglutide and semaglutide) (19, 35, 36).”
BackgroundRecent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Zeynaloo, E., Stone, L. D., Dikici, E., Ricordi, C., Deo, S. K., Bachas, L. G., Daunert, S., & Lanzoni, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101063 · Cited by 27
Clinical pharmacology of imeglimin for the treatment of type 2 diabetes
Johansson, K. S., Brønden, A., Knop, F. K., & Christensen, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729123 · Cited by 23
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
“(16, 46).”
InfluentialKim, H., Ingram, J. L., & Que, L. G. (2023) · Journal of Asthma and Allergy · doi:10.2147/jaa.s402340 · Cited by 24
Boye, K. S., Matza, L. S., Stewart, K. D., Jordan, J. B., Biricolti, G., Santo, S. D., Perez‐Nieves, M., Federici, M. O., Gentilella, R., Losi, S., et al. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1609482 · Cited by 22
“All participants were required to be (1) between 30 and 75 years old; (2) diagnosed with type 2 diabetes; (3) able to provide proof of type 2 diabetes diagnosis; (4) able to understand the assessment procedures; and (5) residing in Italy for the main study or the UK for the pilot study.”
BackgroundHeymsfield, S. B., Raji, A., Gallo, S., Liu, J., Pong, A., Hannachi, H., & Terra, S. G. (2020) · Obesity · doi:10.1002/oby.22748 · Cited by 21
“peptide 1 (GLP-1) receptor agonists (9) and sodium-glucose cotransporter”
BackgroundWeight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions
Zaharieva, D. P., Addala, A., Simmons, K. M., & Maahs, D. M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00411-z · Cited by 21
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases
García, R. D., Asensio, J. A., Perdicaro, D. J., & Peral, M. D. L. Á. (2022) · Current Vascular Pharmacology · doi:10.2174/1570161120666220201160038 · Cited by 22
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Rad, J., & Meléndez‐Torres, G. J. (2025) · BMC Public Health · doi:10.1186/s12889-025-24197-8 · Cited by 22
“One promising class of drugs that has gained attention for their efficacy in promoting weight loss and managing diabetes is Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) [6–10].”
Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210974 · Cited by 21
“As an incretin hormone, GLP-1 plays a fundamental role in glucose homeostasis by stimulating glucose-dependent insulin secretion from pancreatic beta-cells and inhibiting glucagon release, which is the primary mechanism by which GLP-1RAs treat type 2 diabetes [127,128].”
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 21
“Management strategies can be employed to help mitigate potential GI AEs such as nausea, vomiting, and diarrhea [46].”
BackgroundSelf-citationNew insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs
Pinto, S. F. T., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1952 · Cited by 20
Wyse, R. K. H., Isaacs, T., Barker, R. A., Cookson, M., Dawson, T. M., Devos, D., Dexter, D. T., Duffen, J., Federoff, H. J., Fiske, B. K., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230363 · Cited by 18
“Widely used for type 2 diabetes, with a well characterized safety record, GLP-1 receptor agonists have undergoneanextensiveprocesstoimprovetheirphar-macokineticsandpharmacodynamicsforperipheral tissuetargetengagement[12].”
BackgroundMoo, E. V., Møller, T. C., Sørensen, F. A., Inoue, A., & Bräuner‐Osborne, H. (2025) · FEBS Journal · doi:10.1111/febs.17338 · Cited by 21
“GLP-1 regulates post-prandial blood glucose levels, suppresses glucagon secretion, and promotes beta-cell survival and proliferation [2 – 4].”
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 20
“6%) but also effective for weight loss, lowering the risk of hypoglycaemia and inducing small improvements in blood pressure and lipid profiles [35].”
BackgroundExamining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
“Delayed gastric emptying is attributed to activation of GLP-1 receptors in the gastrointestinal tract.(72) GLP-1 RAs also have other pleiotropic effects that contribute to their CV benefit.”
BackgroundSemaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 36
GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo
Arcones, A. C., Vila‐Bedmar, R., Mirasierra, M., Cruces‐Sande, M., Vallejo, M., Jones, B. J., Tomás, A., Mayor, F., & Murga, C. (2021) · BMC Biology · doi:10.1186/s12915-021-00966-w · Cited by 18
Errafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
“Because of this impracticality, various longer-acting GLP-1RAs were developed, and some are now licensed for the treatment of T2D, including exenatide (taken twice daily), liraglutide (provided once daily), and the once-weekly agents albiglutide and dulaglutide [30].”
BackgroundKupai, K., Várkonyi, T. T., Török, S., Gáti, V., Czimmerer, Z., Puskás, L. G., & Szebeni, G. J. (2022) · Life · doi:10.3390/life12081205 · Cited by 19
“The majority of GLP-1 RAs are injectable glucose-lowering agents, with a low-risk of hypoglycemia via the stimulation of GLP-1 receptors leading to an increase in insulin secretion [77].”
BackgroundKo, J., Fonseca, V. A., & Wu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098283 · Cited by 18
Casertano, M., Vito, A., Aiello, A., Imperatore, C., & Menna, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092321 · Cited by 19
Miao, X., Davoudi, M., Alitotonchi, Z., Ahmadi, E. S., Amraee, F., Alemi, A., & Afrisham, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01581-3 · Cited by 20
“In addition, GLP-1RAs have been reported to have a significant reduction of around 1% in HbA1c levels and reduced all-cause mortality in T2DM patients compared to controls [21, 22].”
Mata‐Cases, M., Franch‐Nadal, J., Ortega, E., Real, J., Gratacòs, M., Vlacho, B., & Mauricio, D. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1618806 · Cited by 18
Jeffrey, L. O. (2019) · Clinical Medical Reviews and Case Reports · doi:10.23937/2378-3656/1410281 · Cited by 17
Johansson, K. S., Sonne, D. P., Knop, F. K., & Christensen, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1791078 · Cited by 17
Chauhan, P., Yadav, D., Tayal, S., & Jin, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200826135401 · Cited by 18
Exploring the recent molecular targets for diabetes and associated complications
Gupta, A. K., Behl, T., Sehgal, A., Bhardwaj, S., Singh, S., Sharma, N., & Hafeez, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06294-0 · Cited by 18
Glucose Homeostasis, Diabetes Mellitus, and Gender-Affirming Treatment
Milionis, C., Ilias, Ι., Venaki, E., & Koukkou, E. G. (2023) · Biomedicines · doi:10.3390/biomedicines11030670 · Cited by 18
“Their use is associated with reduction in body weight, whilst it does not carry a risk of hypoglycemia [65].”
Dutt, C., Salles, J. E. N., Joshi, S., Nair, T., Chowdhury, S., Mithal, A., Mohan, V., Kasliwal, R., Sharma, S., Tijssen, J. G. P., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s333787 · Cited by 19
Overview of Peptides and Their Potential Roles in Skin Health and Beauty
Wang, L., Wu, Z., Wang, X., Wang, X., Mao, J., Yan, Y., Zhang, L., & Zhang, Z. (2025) · Journal of Peptide Science · doi:10.1002/psc.3668 · Cited by 16
Santella, C., Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., & Azoulay, L. (2020) · Epidemiology · doi:10.1097/ede.0000000000001196 · Cited by 17
Pereira, S., Martins, A. D., Moreira, B. P., Bernardino, R. L., Barros, A., Monteiro, M. P., Oliveira, P. F., & Alves, M. G. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30230 · Cited by 16
“The paramount role of energy regulatory signals was highlighted after the identification of mutations in several genes involved in these signaling cascades that lead to obesity (Huvenne & Dubern, 2014).”
BackgroundRao, G., & Jensen, E. T. (2020) · Global Pediatric Health · doi:10.1177/2333794x20981343 · Cited by 17
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
“The glycaemic effects, weight reduction and potential CV effects of evolving GLP-1 RAs in the treatment of T2D have been reviewed extensively in the last decade [7, 11, 43].”
BackgroundTrink, J., Li, R., Palarasah, Y., Troyanov, S., Andersen, T. E., Sidelmann, J. J., Inman, M. D., Pizzo, S. V., Gao, B., & Krepinsky, J. C. (2021) · Biomedicines · doi:10.3390/biomedicines9091112 · Cited by 16
Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients
Mohandas, D., Calma, J., Gao, C., & Basina, M. (2023) · Endocrines · doi:10.3390/endocrines4010008 · Cited by 19
Ali, S., Baig, S., Wanninayake, S., Xavier, G. D. S., Dawson, C., Paisey, R., & Geberhiwot, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15398 · Cited by 18
“12,39 Now the question arises what causes the weight loss in ALMS.”
BackgroundInstituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
Feng, J. N., & Jin, T. (2024) · Medical Review · doi:10.1515/mr-2024-0018 · Cited by 18
Marulkar, V. S., & Bhatia, N. M. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10007-3 · Cited by 15
“Thus, the new class of antidiabetics, DPP-4 inhibitors prevent the breakdown of GLP-1, thereby effectively mimicking the action of incretin hormones (Hinnen 2017).”
Xu, X., Chen, J., Li-dong, H., Liang, M., Wang, X., Feng, S., Shen, J., & Luan, X. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.12.012 · Cited by 15
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & SKOLNIK, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 17
Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Hearn, E. B., & Sherman, J. J. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0033 · Cited by 16
“Furthermore, the possibility of once-weekly dosing for glycemic control in type 2 diabetes has been realized with some GLP-1 receptor agonists (semaglutide, exenatide extended-release, and dulaglutide) as a result of albumin binding that decreases renal clearance and protects against metabolic degradation by the dipep…”
BackgroundMetformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 16
Chang, S., Chen, J., Chuang, Y., & Chen, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010166 · Cited by 17
“, Liraglutide, are of particular interest for their glucose-lowering effects, which are useful to the treatment of T2D [49].”
BackgroundCurrent progress in pharmacogenomics of Type 2 diabetes: A systemic overview
Guo, Z., & Priefer, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102239 · Cited by 17
Microbial network inference for longitudinal microbiome studies with LUPINE
Kodikara, S., & Cao, K. L. (2025) · Microbiome · doi:10.1186/s40168-025-02041-w · Cited by 15
“GLP-1 receptor agonists are used as a class of medication to treat type 2 diabetes [59].”
McLaughlin, S. A., Davila, N., Shields, C., Bineshfar, N., Banaee, T., & Williams, B. K. (2025) · Retina · doi:10.1097/iae.0000000000004616 · Cited by 14
Ominous Octet and Other Scary Diabetes Stories
Kelly, S. D., & Neary, S. L. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.002 · Cited by 23
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Drug Repositioning in Friedreich Ataxia
Rufini, A., Malisan, F., Condò, I., & Testi, R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.814445 · Cited by 14
“Incretin mimetics, such as GLP-1 analogues, are currently used for the treatment and management of type 2 diabetes (Hinnen, 2017; Chia and Egan, 2020).”
MethodThe transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells
Bourouh, C., Courty, É., Rolland, L., Pasquetti, G., Gromada, X., Rabhi, N., Carney, C., Moreno, M., Boutry, R., Caron, É., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111170 · Cited by 14
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Hasanzad, M., Sarhangi, N., Nikfar, S., Ostad, S. N., & Meybodi, H. R. A. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00619-9 · Cited by 16
Synthesis of New Valinol‐Derived Sultam Triazoles as α ‐Glucosidase Inhibitors
Jaffery, S. M. F., Khan, M. A., Ullah, N., Wahab, A., Choudhary, M. I., & Basha, F. Z. (2021) · ChemistrySelect · doi:10.1002/slct.202102119 · Cited by 15
Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295639 · Cited by 13
“…et al., 2001) and/or function (Nauck et al., 1986; Muscelli et al., 2008), and GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements to β -cell function and peripheral insulin sensitivity (Zander et al., 2002; Hinnen, 2017).”
BackgroundFeng, J. N., Shao, W., & Jin, T. (2023) · Physiological Reports · doi:10.14814/phy2.15620 · Cited by 14
“Among them, liraglutide (Victoza®) and semaglutide (Ozempic®) are now FDA- approved therapeutic agents for both T2D and chronic weight management (Deacon, 2020; Garber, 2011; Hinnen, 2017).”
BackgroundBoianelli, A., Nordell, P., Earl, J., Naylor, J., Hornigold, D. C., Jansson‐Löfmark, R., & Sundqvist, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101310 · Cited by 15
“GLP-1RAs can now be divided into short-acting (exenatide twice daily, lixisenatide), intermediate (liraglutide), and long-acting (albiglutide, dulaglutide, semaglutide, and exenatide once weekly (QW)) [4,9].”
BackgroundAdvances in Oral Biomacromolecule Therapies for Metabolic Diseases
Jiao, Q., Huang, Y., He, J., & Xu, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020238 · Cited by 13
“GLP-1 also inhibits lipolysis in adipose tissue, thereby reducing circulating free fatty acids, which may help improve the blood lipid profile and reduce the risk of diabetes in patients with CVDs [296,298–300].”
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs
Greco, A., Coperchini, F., Croce, L., Magri, F., Teliti, M., & Rotondi, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303844 · Cited by 18
“Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for T2DM which lower glucose concentrations without weight gain (often with weight loss) and with low risk for hypoglycemia (Hinnen, 2017).”
BackgroundMahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 15
Skeletal muscle disorders as risk factors for type 2 diabetes
Tammineni, E. R., Manno, C. D., Oza, G., & Figueroa, L. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112466 · Cited by 13
Heart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Das, A., Geetha, K. M., & Hazarika, I. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09927-y · Cited by 12
“Incretin effect is mediated by peptide hormones called incretin, which are released in response to nutrients intake from the gut of intestine (Hinnen 2017).”
BackgroundKuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 12
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037510 · Cited by 12
“17 Findings from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial indicate that GLP1-RA reduces cardiovascular events in patients with T2D.”
Ji, L., Du, Y., Xu, M., Zhou, X., Mo, Z., Ma, J., Li, J., Li, Y., Lin, J., Wang, Y., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05392-9 · Cited by 12
Univariate and Multivariate Determination of Dapagliflozin and Saxagliptin in Bulk and Dosage Form
Elhassan, M. M., Mahmoud, A. M., Hegazy, M. A. M., & Mowaka, S. (2022) · Journal of AOAC International · doi:10.1093/jaoacint/qsac143 · Cited by 11
Tzogiou, C., Wieser, S., Eichler, K., Carlander, M., Djalali, S., Rosemann, T. J., & Brändle, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108476 · Cited by 11
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Sharma, B., Kumar, A., Sharma, U., Pal, D., & Prashar, S. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220331152809 · Cited by 11
Exercise Testing in Individuals With Diabetes, Practical Considerations for Exercise Physiologists
Kosinski, C., Besson, C., & Amati, F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01257 · Cited by 13
“Most of these medications have low risk or even no risk of hypoglycemia (Hinnen, 2017; Yang et al., 2017).”
BackgroundDulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
MacIsaac, R. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00863-5 · Cited by 13
Singh, H., Natt, N. K., & Nim, D. K. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2459720 · Cited by 10
Kheira, H. S., El‐Sayed, G., & El‐Adl, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150337 · Cited by 10
Morningstar, J. L., Lauck, B. J., Bank, N., & Lalli, T. A. J. (2025) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2025.05.002 · Cited by 10
Examining the biological causes of eating disorders to inform treatment strategies
Foldi, C. J., & Griffiths, K. R. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00940-3 · Cited by 12
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 22
Potential Therapeutic Targets for the Management of Diabetes Mellitus Type 2
Prabhakar, P. K., & Batiha, G. E. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230501172557 · Cited by 11
Waataja, J. J., Asp, A. J., & Billington, C. J. (2023) · Biomedicines · doi:10.3390/biomedicines11092452 · Cited by 11
“This class of drugs has been used to treat T2DM in the early and advanced stages [27].”
BackgroundWernicke Encephalopathy Associated With Semaglutide Use
Sheth, K., Garza, E., Saju, A., Nazir, N., & Agarwal, A. (2024) · Cureus · doi:10.7759/cureus.61783 · Cited by 10
“It has shown efficacy in glucose control for diabetes mellitus type 2 patients by increasing insulin secretion, lowering glucagon release, and slowing gastric emptying [5].”
BackgroundCazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
“Characteristics of GLP-1RAs approved for the treatment of T2DM [24,30].”
BackgroundLisco, G., Tullio, A. D., Guastamacchia, E., & Triggiani, V. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200705211224 · Cited by 13
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
Harej, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D., & Mršić‐Pelčić, J. (2024) · Pharmaceuticals · doi:10.3390/ph17101313 · Cited by 10
“…to decrease neuroinflammation, excitotoxicity, oxidative stress, and apoptosis in animal models of a wide range of neurological disorders, including autoimmune encephalomyelitis, retinal neurodegeneration, stroke, and ALS of these processes, is also implicated in the progress of secondary TBI [44].”
BackgroundBhimanwar, R. S., Lokhande, K. B., Shrivastava, A., Singh, A., Chitlange, S. S., & Mittal, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2173654 · Cited by 9
“…involves various mechanisms, such as increased availability and sensitivity of insulin, decrease in carbohydrate absorption from the gastrointestinal tract, inhibition of the glucosidase enzyme (Joshi et al., 2015), inhibition of the DPP-4 enzyme (Gallwitz, 2019), GLP-1 agonists (Hinnen, 2017) etc.”
BackgroundMethodGuo, X., Yang, W., Zhang, J., Dong, X., Liu, M. R., Gu, S., Lauand, F., Li, L., Huang, Q., Kang, L., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15074 · Cited by 9
Ahmed, M., Badi, S., Elidrisi, A., Husain, N. E., Zainudin, S. B., Mahmood, A., Abubaker, N. E., Alghamdi, A., & Ahmed, M. H. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01145-6 · Cited by 11
Metadata
- Authors
- Hinnen, D.
- Affiliations
- University of Colorado Health (US)
- Corresponding author
- Hinnen, Deborah
- ORCID
- Hinnen, Deborah
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2017-08-01
- Volume
- 30
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC5556578
- OpenAlex
- W2592545469
- Cited by
- 394
- References
- 53
- Citations by year
- 2026: 23 · 2025: 71 · 2024: 59 · 2023: 57 · 2022: 53 · 2021: 59 · 2020: 46 · 2019: 22 · 2018: 3 · 2017: 1
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, incretin system, exenatide, liraglutide, lixisenatide, exenatide extended-release, albiglutide, dulaglutide, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, patient selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.